注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Artelo Biosciences Inc是一家临床阶段的生物制药公司。该公司专注于开发针对脂质信号通路的疗法,包括内源性大麻素系统(ECS),这是一个受体家族和神经递质,在整个身体中形成生化通讯网络。该公司正在开发一种双大麻素激动剂G蛋白偶联受体(GPCR)靶向合成小分子程序ART27.13,作为与癌症相关的厌食症的潜在治疗方法。该公司的第二个项目ART26.12是来自其脂肪酸结合蛋白抑制剂平台的小分子先导产品候选者,特别是脂肪酸结合蛋白5(FABP5),正在进行临床前研究作为潜在的癌症治疗方法,用于治疗疼痛和炎症以及与焦虑有关的疾病,包括创伤后应激障碍。此外,该公司还在开发ART12.11(CBD 共晶),它是大麻二酚(CBD)的固态组合物。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Saoirse Elizabeth O’Sullivan | - | - | Member of Scientific Advisor Board |
Iwoa Ojima | - | 2019 | Scientific Advisor |
Iwao Ojima | - | 2021 | Member of the Advisory Board |
Robert Martin Emanuele | 67 | 2017 | Independent Director |
Douglas W. Blayney | 71 | 2017 | Independent Director |
Martin Kaczocha | - | 2019 | Member of Scientific Advisory Board |
Connie L. Matsui | 67 | 2017 | Independent Chairperson of the Board |
Iwao Ojima | - | 2021 | Member of the Advisory Board |
Steven Kelly | 56 | 2017 | Independent Director |
Gregory D. Gorgas | 58 | 2017 | President, CEO, CFO, Treasurer, Secretary & Director |
Tamara A. Seymour | 62 | 2021 | Independent Director |
Steven Laviolette | - | - | Member of Scientific Advisor Board |
Richard K. Porter | - | 2020 | Member of Scientific Advisory Board |
Gregory R. Reyes | - | 2020 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核